ESR1 and breast carcinoma: Proteomic analysis of breast cancer cell lines harboring Y537N and Y537S ER mutations has revealed a significant upregulation of immune-related pathways, along with increased proliferation signaling and activation of key kinases, particularly mTOR and CDKs.